{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:53:16Z","timestamp":1791366796844,"version":"4.3.1"},"reference-count":99,"publisher":"European Respiratory Society (ERS)","issue":"182","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Bronchiectasis (BE) is a heterogeneous lung disease characterised by chronic neutrophilic inflammation. A \u201cvicious vortex\u201d develops through the interactions between neutrophilic inflammation, infection and impaired mucociliary clearance, leading to progressive structural lung damage and worsening lung function. As part of this neutrophilic inflammation, neutrophil serine proteases (NSPs) overwhelm their natural inhibitors, with high NSP levels being associated with pulmonary exacerbations in people with BE. NSPs, activated by dipeptidyl peptidase 1 (DPP1) during neutrophil maturation in the bone marrow, are released from neutrophils at sites of inflammation. Pharmacological inhibition of DPP1 is a compelling approach to reduce neutrophilic inflammation in BE. Three DPP1 inhibitors have had favourable results in clinical studies for BE, namely brensocatib, florensocatib and verducatib, with recent approval of brensocatib, a first-in-class DPP1 inhibitor, in the US and Europe, providing a promising treatment option for people with BE. Many questions about DPP1 inhibition remain, including long-term efficacy and safety, and efficacy in people with cystic fibrosis, primary COPD and immunodeficiencies, who were generally excluded from prior large studies. Despite the availability of cystic fibrosis transmembrane conductance regulator modulator therapy, many people with cystic fibrosis continue to have pulmonary exacerbations. The inclusion of a broad population with a range of aetiologies is key in the development of DPP1 inhibitors to support access to treatment for all those who could benefit. This review explores the current DPP1 inhibition landscape, discussing the clinical studies to date for these three novel DPP1 inhibitors and the evolution of DPP1 studies in BE.<\/jats:p>","DOI":"10.1183\/16000617.0213-2026","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:20:16Z","timestamp":1791364816000},"page":"260213","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The dipeptidyl peptidase 1 inhibition landscape in bronchiectasis and its future direction"],"prefix":"10.1183","volume":"35","author":[{"given":"James D.","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2026100702200957000_35.182.260213.1","doi-asserted-by":"crossref","first-page":"104174","DOI":"10.1016\/j.lpm.2023.104174","article-title":"Bronchiectasis","volume":"52","author":"Barbosa","year":"2023","journal-title":"Presse Med"},{"key":"2026100702200957000_35.182.260213.2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-2600(24)00176-0","article-title":"Rethinking bronchiectasis as an inflammatory disease","volume":"12","author":"Long","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026100702200957000_35.182.260213.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"key":"2026100702200957000_35.182.260213.4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0120-2019"},{"key":"2026100702200957000_35.182.260213.5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","article-title":"Bronchiectasis","volume":"4","author":"Chalmers","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026100702200957000_35.182.260213.6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","article-title":"Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)","volume":"11","author":"Chalmers","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026100702200957000_35.182.260213.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31767-7"},{"key":"2026100702200957000_35.182.260213.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01269-2018"},{"key":"2026100702200957000_35.182.260213.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107503"},{"key":"2026100702200957000_35.182.260213.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201303-0411CI"},{"key":"2026100702200957000_35.182.260213.11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115996"},{"key":"2026100702200957000_35.182.260213.12","doi-asserted-by":"crossref","first-page":"00633","DOI":"10.1183\/23120541.00633-2022","article-title":"A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf","volume":"9","author":"Chalmers","year":"2023","journal-title":"ERJ Open Res"},{"key":"2026100702200957000_35.182.260213.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201712-2423OC"},{"key":"2026100702200957000_35.182.260213.14","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.002733"},{"key":"2026100702200957000_35.182.260213.15","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0257-2024"},{"key":"2026100702200957000_35.182.260213.16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12890-018-0668-7","article-title":"Heparin-binding protein in sputum as a marker of pulmonary inflammation, lung function, and bacterial load in children with cystic fibrosis","volume":"18","author":"Hovold","year":"2018","journal-title":"BMC Pulmonary Medicine"},{"key":"2026100702200957000_35.182.260213.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1785"},{"key":"2026100702200957000_35.182.260213.18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fimmu.2019.00423","article-title":"Caught in a trap? Proteomic analysis of neutrophil extracellular traps in rheumatoid arthritis and systemic lupus erythematosus","volume":"10","author":"Chapman","year":"2019","journal-title":"Front Immunol"},{"key":"2026100702200957000_35.182.260213.19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S2213-2600(25)00334-0","article-title":"Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study","volume":"14","author":"Shoemark","year":"2026","journal-title":"Lancet Respir Med"},{"key":"2026100702200957000_35.182.260213.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01050-2024"},{"key":"2026100702200957000_35.182.260213.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00081-2025"},{"key":"2026100702200957000_35.182.260213.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202310-1729OC"},{"key":"2026100702200957000_35.182.260213.23","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1002\/hsr2.581","article-title":"Sputum neutrophil elastase and its relation to pediatric bronchiectasis severity: a cross-sectional study","volume":"5","author":"Ali","year":"2022","journal-title":"Health Sci Rep"},{"key":"2026100702200957000_35.182.260213.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC"},{"key":"2026100702200957000_35.182.260213.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2202OC"},{"key":"2026100702200957000_35.182.260213.26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12890-019-0818-6","article-title":"The economic burden of bronchiectasis \u2013 known and unknown: a systematic review","volume":"19","author":"Goeminne","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026100702200957000_35.182.260213.27","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0049-2024"},{"key":"2026100702200957000_35.182.260213.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01551-2024"},{"key":"2026100702200957000_35.182.260213.29","unstructured":"US Food and Drug Administration . BRINSUPRI\u2122 (brensocatib) prescribing information. Date last accessed: 5 November 2025. Date last updated: August 2025. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217673s000lbl.pdf"},{"key":"2026100702200957000_35.182.260213.30","unstructured":"European Medicines Agency . Brinsupri: EPAR \u2013 product information. Date last accessed: 30 January 2026. Date last updated: 4 December 2025. www.ema.europa.eu\/en\/documents\/product-information\/brinsupri-epar-product-information_en.pdf"},{"key":"2026100702200957000_35.182.260213.31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.704173"},{"key":"2026100702200957000_35.182.260213.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200607-995OC"},{"key":"2026100702200957000_35.182.260213.33","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202432"},{"key":"2026100702200957000_35.182.260213.34","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.289"},{"key":"2026100702200957000_35.182.260213.35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00148-2015"},{"key":"2026100702200957000_35.182.260213.36","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01401-4"},{"key":"2026100702200957000_35.182.260213.37","doi-asserted-by":"crossref","first-page":"00574","DOI":"10.1183\/23120541.00574-2020","article-title":"Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics","volume":"7","author":"Faverio","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026100702200957000_35.182.260213.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.12.009"},{"key":"2026100702200957000_35.182.260213.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.03.009"},{"key":"2026100702200957000_35.182.260213.40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200213462"},{"key":"2026100702200957000_35.182.260213.41","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13515"},{"key":"2026100702200957000_35.182.260213.42","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0241-2021"},{"key":"2026100702200957000_35.182.260213.43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1239151"},{"key":"2026100702200957000_35.182.260213.44","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.36.12.881"},{"key":"2026100702200957000_35.182.260213.45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76009"},{"key":"2026100702200957000_35.182.260213.46","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2009.03.016","article-title":"Papillon\u2013Lef\u00e8vre syndrome: clinical presentation and a brief review","volume":"108","author":"Dhanrajani","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2026100702200957000_35.182.260213.47","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100702200957000_35.182.260213.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021713"},{"key":"2026100702200957000_35.182.260213.49","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2213-2600(25)00019-0","article-title":"Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"13","author":"Zhong","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026100702200957000_35.182.260213.50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22095018"},{"key":"2026100702200957000_35.182.260213.51","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906-1190PP"},{"key":"2026100702200957000_35.182.260213.52","unstructured":"ClinicalTrials.gov . Clairleaf\u2122: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this medicine. Date last accessed: 29 October 2025. Date last updated: 4 August 2026. https:\/\/clinicaltrials.gov\/study\/NCT05846230"},{"key":"2026100702200957000_35.182.260213.53","unstructured":"ClinicalTrials.gov . A study to test how well BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis (Clairafly\u2122). Date last accessed: 7 September 2023. Date last updated: 23 June 2026. https:\/\/clinicaltrials.gov\/study\/NCT05865886"},{"key":"2026100702200957000_35.182.260213.54","unstructured":"ClinicalTrials.gov . The AIRTIVITY\u2122 study: A study to find out whether BI 1291583 helps people with bronchiectasis. Date last accessed: 5 November 2025. Date last updated: 6 August 2026. https:\/\/clinicaltrials.gov\/study\/NCT06872892"},{"key":"2026100702200957000_35.182.260213.55","unstructured":"Insmed . FDA approves BRINSUPRI\u2122 (brensocatib) as the first and only treatment for non-cystic fibrosis bronchiectasis, a serious, chronic lung disease. Date last accessed: 5 November 2025. Date last updated: 12 August 2025. https:\/\/investor.insmed.com\/2025-08-12-FDA-Approves-BRINSUPRI-TM-brensocatib-as-the-First-and-Only-Treatment-for-Non-Cystic-Fibrosis-Bronchiectasis,-a-Serious,-Chronic-Lung-Disease"},{"key":"2026100702200957000_35.182.260213.56","unstructured":"Insmed . European Commission approves BRINSUPRI\u2122 (brensocatib) as the first and only treatment approved for non-cystic fibrosis bronchiectasis in the European Union. Date last accessed: 30 January 2026. Date last updated: 18 November 2025. https:\/\/investor.insmed.com\/2025-11-18-European-Commission-Approves-BRINSUPRI-TM-brensocatib-as-the-First-and-Only-Treatment-Approved-for-Non-Cystic-Fibrosis-Bronchiectasis-in-the-European-Union"},{"key":"2026100702200957000_35.182.260213.57","doi-asserted-by":"crossref","unstructured":"Zhong N-s , Cao J , Feng Y , et al. Florensocatib in adults with bronchiectasis: The HOPE-BE trial protocol and baseline demographic characteristics. ERJ Open Res 2026; 12: 00182\u20132026. doi:10.1183\/23120541.00182-2026","DOI":"10.1183\/23120541.00182-2026"},{"key":"2026100702200957000_35.182.260213.58","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02444-z"},{"key":"2026100702200957000_35.182.260213.59","doi-asserted-by":"crossref","first-page":"A7421","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7421","article-title":"Exacerbation rate and lung function in adolescent patients with non-cystic fibrosis bronchiectasis: an analysis of the ASPEN trial","volume":"211","author":"Maitre","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100702200957000_35.182.260213.60","doi-asserted-by":"crossref","first-page":"00151","DOI":"10.1183\/23120541.00151-2024","article-title":"Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics","volume":"10","author":"Chalmers","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026100702200957000_35.182.260213.61","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s40262-025-01550-z","article-title":"A phase IIa, single-blind, placebo-controlled, parallel-group study to assess safety, tolerability, and pharmacokinetics\/pharmacodynamics of brensocatib in adults with cystic fibrosis","volume":"64","author":"Konstan","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026100702200957000_35.182.260213.62","unstructured":"ClinicalTrials.gov . A study to assess the efficacy and safety of HSK31858 in participants with non-cystic fibrosis bronchiectasis. Date last accessed: 4 March 2025. Date last updated: 28 October 2024. https:\/\/clinicaltrials.gov\/study\/NCT06660992"},{"key":"2026100702200957000_35.182.260213.63","doi-asserted-by":"crossref","unstructured":"Chalmers JD , Shteinberg M , Chotirmall SH , et al. Phase III AIRTIVITY study design \u2013 verducatib (BI 1291583) in people with bronchiectasis. ERJ Open Res 2026; 12: 01068\u20132025. doi:10.1183\/23120541.01068-2025","DOI":"10.1183\/23120541.01068-2025"},{"key":"2026100702200957000_35.182.260213.64","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01126-2025"},{"key":"2026100702200957000_35.182.260213.65","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01774-4"},{"key":"2026100702200957000_35.182.260213.66","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13891"},{"key":"2026100702200957000_35.182.260213.67","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jcf.2025.03.675","article-title":"WS19.05 A Phase II trial (CLAIRAFLY) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase 1 inhibitor BI 1291583 in adults with bronchiectasis due to cystic fibrosis","volume":"24","author":"Mall","year":"2025","journal-title":"J Cystic Fibrosis"},{"key":"2026100702200957000_35.182.260213.68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01608-2"},{"key":"2026100702200957000_35.182.260213.69","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219943"},{"key":"2026100702200957000_35.182.260213.70","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00616-2025"},{"key":"2026100702200957000_35.182.260213.71","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0001-2024"},{"key":"2026100702200957000_35.182.260213.72","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2025.PA4960"},{"key":"2026100702200957000_35.182.260213.73","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026100702200957000_35.182.260213.74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3"},{"key":"2026100702200957000_35.182.260213.75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301725"},{"key":"2026100702200957000_35.182.260213.76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2026100702200957000_35.182.260213.77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2026100702200957000_35.182.260213.78","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0392OC"},{"key":"2026100702200957000_35.182.260213.79","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02435-2024"},{"key":"2026100702200957000_35.182.260213.80","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135\u2005years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100702200957000_35.182.260213.81","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02029-2022"},{"key":"2026100702200957000_35.182.260213.82","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01609-4"},{"key":"2026100702200957000_35.182.260213.83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ajrccm\/aamaf001","article-title":"Elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a Phase 3, double-blind, randomized, placebo-controlled trial and real-world study","volume":"212","author":"Castellani","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100702200957000_35.182.260213.84","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01783-2025"},{"key":"2026100702200957000_35.182.260213.85","unstructured":"Cystic Fibrosis Foundation . 2024 Patient Registry Annual Data Report. Bethesda, Maryland, Cystic Fibrosis Foundation, 2025."},{"key":"2026100702200957000_35.182.260213.86","unstructured":"European Medicines Agency . Kaftrio (elexacaftor\/tezacaftor\/ivacaftor) summary of product characteristics. Date last accessed: 5 November 2025. Date last updated: 19 March 2026. www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_en.pdf"},{"key":"2026100702200957000_35.182.260213.87","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022"},{"key":"2026100702200957000_35.182.260213.88","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1513\/AnnalsATS.202507-817OC","article-title":"Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Sagel","year":"2025","journal-title":"Ann Am Thorac Soc"},{"key":"2026100702200957000_35.182.260213.89","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026100702200957000_35.182.260213.90","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jcf.2025.03.492","article-title":"WS01.01 Predicting future pulmonary exacerbation (PEx) rates for cystic fibrosis (CF) clinical trials","volume":"24","author":"VanDevanter","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026100702200957000_35.182.260213.91","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202408-800FR"},{"key":"2026100702200957000_35.182.260213.92","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01349-2025"},{"key":"2026100702200957000_35.182.260213.93","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-2600(26)00077-9","article-title":"Ten unanswered questions about dipeptidyl peptidase-1 inhibition in bronchiectasis","volume":"14","author":"He","year":"2026","journal-title":"Lancet Respir Med"},{"key":"2026100702200957000_35.182.260213.94","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1053"},{"key":"2026100702200957000_35.182.260213.95","unstructured":"ClinicalTrials.gov . Assessment of INS1007 in participants with non-cystic fibrosis bronchiectasis. Date last accessed: 26 June 2024. Date last updated: 27 March 2023. https:\/\/clinicaltrials.gov\/study\/NCT03218917"},{"key":"2026100702200957000_35.182.260213.96","unstructured":"ClinicalTrials.gov . A study to assess the safety, tolerability, and pharmacokinetics of brensocatib tablets in adults with cystic fibrosis. Date last accessed: 5 July 2023. Date last updated: 12 March 2026. https:\/\/clinicaltrials.gov\/study\/NCT05090904"},{"key":"2026100702200957000_35.182.260213.97","unstructured":"ClinicalTrials.gov . A study to assess the efficacy, safety, and tolerability of brensocatib in participants with non-cystic fibrosis bronchiectasis (ASPEN). Date last accessed: 26 June 2024. Date last updated: 16 December 2025. https:\/\/clinicaltrials.gov\/study\/NCT04594369"},{"key":"2026100702200957000_35.182.260213.98","unstructured":"ClinicalTrials.gov . A study of HSK31858 in participants with non-cystic fibrosis bronchiectasis. Date last accessed: 26 June 2024. Date last updated: 26 September 2024. https:\/\/clinicaltrials.gov\/study\/NCT05601778"},{"key":"2026100702200957000_35.182.260213.99","unstructured":"ClinicalTrials.gov . A study to test whether different doses of BI 1291583 help people with bronchiectasis. Date last accessed: 26 June 2024. Date last updated: 28 July 2026. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05238675"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0213-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:20:29Z","timestamp":1791364829000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0213-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":99,"journal-issue":{"issue":"182","published-online":{"date-parts":[[2026,10,7]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1183\/16000617.0213-2026"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0213-2026","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}